Equities

Sun Pharma Advanced Research Co Ltd

Sun Pharma Advanced Research Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)218.95
  • Today's Change0.45 / 0.21%
  • Shares traded262.31k
  • 1 Year change-5.62%
  • Beta1.5692
Data delayed at least 15 minutes, as of Sep 20 2024 10:41 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast

The one analyst offering a 12 month price target expects Sun Pharma Advanced Research Co Ltd share price to rise to 1,370.00 in the next year from the last price of 218.50.
High527.0%1,370.00
Med527.0%1,370.00
Low527.0%1,370.00

Earnings history & estimates in INR

While analysts are not providing 1st quarter earnings estimates for Sun Pharma Advanced Research Co Ltd, they are predicting full year 2025 earnings of 47.00 per share. On Aug 05, 2024, Sun Pharma Advanced Research Co Ltd reported 1st quarter 2025 losses of -- per share.
More ▼

Revenue history & estimates in INR

Revenue forecasts are not available for Sun Pharma Advanced Research Company Limited.
Average growth rate+21.23%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.